AMO: limited recall of Healon D

Article

Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.

Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.

AMO has already notified customers who are in possession of Healon D from the batch in question. The rest of the lot has been removed from AMO's inventory, and AMO is planning to notify the FDA.

According to the manufacturers, the adverse events - ocular inflammation at one day postoperatively - are restricted to a single batch of Healon D. No such reactions have been reported in Europe, and no other AMO viscoelastic products have been affected.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.